Opendata, web and dolomites

CRUZIVAX SIGNED

Vaccine for prevention and treatment of Trypanosoma cruzi infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CRUZIVAX project word cloud

Explore the words cloud of the CRUZIVAX project. It provides you a very rough idea of what is the project "CRUZIVAX" about.

mild    chagas    suburban    reports    19    decoy    cgmp    benznidazole    bridge    lacking    settings    restricted    volunteers    primates    21    immunogenicity    locally    rural    carriers    first    migration    health    acute    difficult    healthy    11    latin    safety    trial    formulations    chronicity    chimeric    active    poor    cruzi    largely    unnoticed    self    cruzivax    profile    efficient    engineered    burden    30    usa    adjuvant    limited    trivalent    activation    therapy    cellular    models    immune    reducing    stimulating    combined    gap    humoral    gt    strengthen    symptoms    trypanosoma    sequences    vi    mice    mass    dogs    infection    became    interruption    clinical    therapeutic    conduct    structure    worldwide    parasitic    caused    million    drug    human    treatment    americas    morbidity    vaccine    proven    social    pipeline    prophylactic    perform    free    immunity    manufacturing    carry    economic    protect    endemic    preclinical    facilitated    disease    critical    antigen    chronic    needle    countries    efficacy    economics    cardiac    infections    american    formulation    performing    000   

Project "CRUZIVAX" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 0 €
 EC max contribution 8˙391˙240 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2024-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 2˙070˙198.00
2    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 963˙795.00
3    ASA SPEZIALENZYME GMBH DE (WOLFENBUTTEL) participant 951˙500.00
4    ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG HU (DUNAKESZI) participant 863˙592.00
5    GENIBET - BIOPHARMACEUTICALS SA PT (OEIRAS) participant 861˙249.00
6    UNIVERSIDAD DE BUENOS AIRES AR (BUENOS AIRES) participant 745˙500.00
7    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 577˙302.00
8    UNIVERSIDADE NOVA DE LISBOA PT (LISBOA) participant 442˙206.00
9    INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA PT (OEIRAS) participant 352˙356.00
10    VAKZINE PROJEKT MANAGEMENT GMBH DE (HANNOVER) participant 310˙137.00
11    FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA ES (BARCELONA) participant 253˙401.00

Map

 Project objective

Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden in the Americas (>11,000,000 chronic infections) and the first cause of cardiac morbidity in poor rural/suburban areas. It became a worldwide concern as a result of mass migration with reports in 19 non-endemic areas (>1.3 million carriers in EU/USA). Treatment is difficult since acute infections have mild symptoms and remain largely unnoticed evolving to chronicity. Drug therapy is also long, often associated with side effects (10-30% interruption) and only active during early infection. The main objective of CRUZIVAX is to bridge the gap between preclinical and clinical development by performing preclinical and clinical phase 1 studies of a needle-free vaccine against T. cruzi with proven efficacy in preclinical models. The vaccine is based on a structure-engineered trivalent chimeric antigen lacking immune decoy sequences and an adjuvant promoting self-limited locally-restricted immune activation stimulating humoral and cellular immunity, which is expected to protect as prophylactic or therapeutic (combined with Benznidazole) vaccine. To achieve this CRUZIVAX will: (i) conduct preclinical studies in mice to assess immunogenicity and efficacy of different vaccine formulations in prophylactic and therapeutic settings, (ii) analyse the immunogenicity and efficacy of the best vaccine formulation in dogs and non-human primates, (iii) produce cGMP antigen and adjuvant by cost-efficient manufacturing (facilitated uptake by health systems with limited resources), (iv) perform a preclinical safety assessment of the vaccine, (v) conduct a phase 1 vaccine clinical trial in healthy volunteers, and (vi) carry out a health economics analysis to identify critical target-product profile parameters. The vaccine will strengthen the pipeline of products for Chagas disease, aimed at reducing disease burden and its social and economic impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRUZIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CRUZIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ORGANTRANS (2020)

Controlled Organoids transplantation as enabler for regenerative medicine translation

Read More  

EXPERT (2019)

EXpanding Platforms for Efficacious mRNA Therapeutics

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More